SAR228810 / Sanofi - LARVOL DELTA

Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer's disease immunotherapeutics. (PubMed, Acta Neuropathol Commun) - "To test this principle, we directly compared 5 clinical antibodies (aducanumab, bapineuzumab,  BAN2401, gantenerumab, and SAR228810) together with an in-house aggregate-preferring antibody (1C22) and established relative ECs in protecting human neurons from human Aβ. Their relative efficacies in this morphological assay were paralleled by their functional ability to rescue oAβ-induced inhibition of hippocampal synaptic plasticity. This novel paradigm provides an unbiased, all-human system for selecting candidate antibodies for advancement to human immunotherapy."

Journal • Alzheimer's Disease • CNS Disorders

SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). (PubMed, Alzheimers Res Ther) - "Based on the improved efficacy/safety profile in non-clinical models of SAR228810, a first-in-man single and multiple dose administration clinical study has been initiated in AD patients."

Journal

Sanofi delivers 2018 business EPS growth of 5.1% at CER (PRNewswire) - "Several projects in phase 1 were stopped...SAR228810, an anti protofibrillar AB mAb for Alzheimer disease..."

Discontinuation

Product discontinued (Sanofi Press Release) - P1, Alzheimer's Disease

Discontinuation